Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs,

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 sales and profit outlook, which resulted in a record stock drop, a proposed class action said.